
Advanced heart failure leads to significant limitations, affecting functional status, quality of life, and survival, despite optimal medical treatment with evidence-based therapies.
Alexander Kantorovich, PharmD, BCPS, is a Clinical Associate Professor of Pharmacy Practice at Chicago State University College of Pharmacy and Clinical Pharmacy Specialist at Advocate Christ Medical Center in Oak Lawn, Illinois. Dr. Kantorovich earned his Associate of Science degree with an emphasis in chemistry from William Rainey Harper College and received his Doctor of Pharmacy degree from the University of Illinois at Chicago College of Pharmacy. He went on to complete a 2-year pharmacotherapy residency with an emphasis in cardiology and critical care at the Cleveland Clinic and is board certified in pharmacotherapy. His research interests center around cardiovascular pharmacotherapy, anticoagulation, and anticoagulation reversal.

Advanced heart failure leads to significant limitations, affecting functional status, quality of life, and survival, despite optimal medical treatment with evidence-based therapies.

Anticoagulation for Mechanical Heart Valves During Pregnancy

Which LVAD type is better?

Although it can lead to death, PCP is preventable with appropriate prophylaxis therapy given to patients at high risk of infection.

What Causes More Opioid Misuse: Higher Doses or Longer Durations?

Both negative and positive outcomes have been observed in studies.

Studies explore the efficacy and safety of anticoagulation for atrial fibrillation in hemodialysis.

DOACs For Treatment of Venous Thromboembolism in Cancer

Contrast-induced nephropathy manifests as a relative increase in serum creatinine of at least 25% above baseline without other precipitating causes.

Pneumonia is a leading cause of hospital admissions and healthcare resource consumption worldwide.

As the role and utilization of dual antiplatelet therapy increases, the rate of gastrointestinal bleeding events are also expected to rise.

A recent systematic review and meta-analysis evaluated the benefits and harms of adjunctive corticosteroids in community acquired pneumonia in 6 different trials.

A consensus document has been published, which gives clinicians the first set of viable guidelines to follow.

This may be the first drug shown to reduce mortality in the HFpEF population in the United States but will hopefully not be the last.

Like other non-steroidal anti-inflammatory drugs (NSAIDs), ketorolac works on cyclooxygenase enzymes (COX) and inhibits prostaglandin synthesis.

Apixaban Dosing in Dialysis

Morphine and Ticagrelor Drug Interaction

The Changing Landscape of Beta Blockers in Cirrhosis

The Changing Landscape of Beta Blockers in Cirrhosis

Published: February 13th 2017 | Updated:

Published: February 2nd 2017 | Updated:

Published: April 4th 2017 | Updated:

Published: May 30th 2017 | Updated:

Published: June 15th 2017 | Updated:

Published: August 25th 2017 | Updated: